Register by January 24 to save up to $1200
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Stephen Groskreutz, PhDSenior Director of Analytical Development in Bioproduct Research and Development at Eli Lilly and CompanySpeaker
Profile
Steve Groskreutz, Ph.D. is the Senior Director of Analytical Development in Bioproduct Research and Development at Eli Lilly and Company. Steve joined Lilly as a post-doctoral scientist in 2017 after receiving his Ph.D. in Analytical Chemistry from the University of Pittsburgh. In 2018 he transitioned to a research scientist within the drug substance process analytical team where he accelerated the technical development and implementation of integrated, process analytical technology (PAT)-centric impurity control strategies for synthetic peptide manufacturing. He established foundational analytical and PAT platforms that were transferrable across the synthetic peptide portfolio and was key to establishing Lilly’s peptide synthesizer platforms. Since 2023, Steve has provided technical and organizational leadership for analytical development teams across synthetic and biologic modalities within Eli Lilly and Company’s Product Research and Development organization.
Agenda Sessions
Continuous Manufacturing of Tirzepatide Using Online UHPLC-Based PAT: An Enabling Technology for Commercialization of a Synthetic Peptide
, 1:35pmView Session